Genmab AS (Denmark) Price Prediction

GMAB Stock  DKK 2,043  2.00  0.1%   
As of today, the value of RSI of Genmab AS's share price is approaching 49. This usually indicates that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Genmab AS's stock, making its price go up or down.

Oversold Vs Overbought

49

 
Oversold
 
Overbought
Genmab AS stock price prediction is an act of determining the future value of Genmab AS shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Genmab AS's future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Genmab AS and does not consider all of the tangible or intangible factors available from Genmab AS's fundamental data. We analyze noise-free headlines and recent hype associated with Genmab AS, which may create opportunities for some arbitrage if properly timed.
It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of Genmab AS based on different types of headlines from major news networks to social media. The Genmab stock price prediction module provides an analysis of price elasticity to changes in media outlook on Genmab AS over a specific investment horizon. Using Genmab AS hype-based prediction, you can estimate the value of Genmab AS from the perspective of Genmab AS response to recently generated media hype and the effects of current headlines on its competitors.
This module is based on analyzing investor sentiment around taking a position in Genmab AS. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in Genmab AS to buy its stock at a price that has no basis in reality. In that case, they are not buying Genmab because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Genmab AS after-hype prediction price

    
  DKK 2043.0  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Genmab AS Basic Forecasting Models to cross-verify your projections.
To learn how to invest in Genmab Stock, please use our How to Invest in Genmab AS guide.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Genmab AS's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Genmab AS in the context of predictive analytics.
Intrinsic
Valuation
LowRealHigh
1,7721,7742,247
Details
Naive
Forecast
LowNextHigh
2,1102,1122,114
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1,9922,0742,156
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Genmab AS. Your research has to be compared to or analyzed against Genmab AS's peers to derive any actionable benefits. When done correctly, Genmab AS's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Genmab AS.

Genmab AS After-Hype Price Prediction Density Analysis

As far as predicting the price of Genmab AS at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Genmab AS or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Genmab AS, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Genmab AS Estimiated After-Hype Price Volatility

In the context of predicting Genmab AS's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Genmab AS's historical news coverage. Genmab AS's after-hype downside and upside margins for the prediction period are 2,041 and 2,045, respectively. We have considered Genmab AS's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
2,043
2,043
After-hype Price
2,045
Upside
Genmab AS is very steady at this time. Analysis and calculation of next after-hype price of Genmab AS is based on 3 months time horizon.

Genmab AS Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Genmab AS is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Genmab AS backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Genmab AS, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.05 
1.92
 0.00  
 0.00  
0 Events / Month
0 Events / Month
In a few days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
2,043
2,043
0.00 
0.00  
Notes

Genmab AS Hype Timeline

Genmab AS is currently traded for 2,043on Copenhagen Exchange of Denmark. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Genmab estimated not to react to the next headline with the price going to stay at about the same level and average media hype impact volatility of insignificant. The immediate return on the next newsis estimated to be very small whereas the daily expected return is currently at -0.05%. The volatility of relative hype elasticity to Genmab AS is about 0.0%. The volatility of related hype on Genmab AS is about 0.0% with expected price after next announcement by competition of 2043.0. About 50.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.19. Genmab AS recorded earning per share (EPS) of 83.21. The entity had not issued any dividends in recent years. Assuming the 90 days trading horizon the next estimated press release will be in a few days.
Check out Genmab AS Basic Forecasting Models to cross-verify your projections.
To learn how to invest in Genmab Stock, please use our How to Invest in Genmab AS guide.

Genmab AS Related Hype Analysis

Having access to credible news sources related to Genmab AS's direct competition is more important than ever and may enhance your ability to predict Genmab AS's future price movements. Getting to know how Genmab AS rivals react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Genmab AS may potentially react to the hype associated with one of its peers.

Genmab AS Additional Predictive Modules

Most predictive techniques to examine Genmab price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Genmab using various technical indicators. When you analyze Genmab charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Genmab AS Predictive Indicators

The successful prediction of Genmab AS stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Genmab AS, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Genmab AS based on analysis of Genmab AS hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Genmab AS's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Genmab AS's related companies.

Story Coverage note for Genmab AS

The number of cover stories for Genmab AS depends on current market conditions and Genmab AS's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Genmab AS is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Genmab AS's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Other Macroaxis Stories

Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios

Genmab AS Short Properties

Genmab AS's future price predictability will typically decrease when Genmab AS's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Genmab AS often depends not only on the future outlook of the potential Genmab AS's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Genmab AS's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding66 M
Cash And Short Term Investments19.3 B
When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:
Check out Genmab AS Basic Forecasting Models to cross-verify your projections.
To learn how to invest in Genmab Stock, please use our How to Invest in Genmab AS guide.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Genmab Stock analysis

When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.